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Aspergillus fumigatus is a saprobic fungus that may cause allergic syndromes, chronic pulmo-
nary aspergillosis (CPA), and acute invasive aspergillosis (IA). Many patients suffering from
aspergillus diseases benefit from antifungal therapy. Itraconazole, voriconazole, posaconazole,
and isavuconazole have been shown to be the most effective compounds for prevention and
treatment of the various aspergillus diseases. The use of alternative antifungal drugs, i.e., lipo-
somal amphotericin B, is limited by toxicity and the echinocandins by fungistatic activity,
while both also require intravenous access. As a consequence, the triazoles have become the
recommended option for first-line therapy and chemoprophylaxis [1,2].
Unfortunately, the effective use of triazoles has been threatened by the emergence of resis-
tance in A. fumigatus [3]. In voriconazole-treated patients, day 42 survival was 21% lower in
voriconazole-resistant IA compared with voriconazole-susceptible infection [4]. As the num-
ber of available drug classes is already very limited, some aspergillus diseases, such as central
nervous system IA, are virtually untreatable if caused by a triazole-resistant isolate.
How is triazole resistance selected in A. fumigatus?
Triazoles represent a stress factor to the fungus that can be overcome by genetic adaptation,
i.e., the acquisition of heritable modifications through natural selection, enabling the fungus to
survive and reproduce in the azole-containing environment. Mutation is thus an important
requirement for adaptation as genetic variations are created that might be better suited to sur-
vive in the presence of azoles. A. fumigatus can benefit from three reproduction modes that
create this variation [5]. Asexual sporulation allows spontaneous mutations to occur in each
one of the many produced spores, while, in addition, extensive genetic reshuffling takes place
through recombination during sexual and parasexual reproduction. Asexual sporulation is
abundant in A. fumigatus, but the frequency and conditions that support (para)sexual repro-
duction remain largely unknown [5]. When A. fumigatus is exposed to triazoles in experimen-
tal conditions, resistance mutations may emerge both through asexual reproduction and
sexual reproduction [6], indicating that both modes enable adaptation to the azole environ-
ment. Resistance generally comes with a fitness cost and reduced growth rates are observed in
resistant isolates recovered from triazole-treated patients when grown in the absence of tria-
zoles [5,7]. Although these isolates have an advantage in the azole environment, they will
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generally not be able to compete with wild-type isolates in the absence of triazoles. Experimen-
tal evolution experiments, however, showed that resistant isolates often undergo compensatory
evolution when growing in the azole-free environment, thus compensating for the fitness cost
[5]. These evolutionary trajectories ultimately benefit the fungus as it enables A. fumigatus to
persist in both azole-containing and azole-free environments [5].
Which azole resistance mechanisms are found in A. fumigatus?
Several resistance mechanisms have been described in A. fumigatus involving mutations
related to the azole target lanosterol 14α-demethylase (Cyp51A), HapE [8], Hmg1 [9], overex-
pression of efflux transporters, and increased target enzyme expression [10]. The diversity of
resistance mechanisms underscores the potential of A. fumigatus to adapt, and it is likely that
more currently uncharacterized mechanisms exist, as in 20%–50% of resistant phenotypes, a
resistance mutation cannot be identified [10]. Cyp51A target enzyme alterations are the most
commonly encountered resistance mechanisms in A. fumigatus isolates. The target enzyme
changes include nonsynonymous single-nucleotide mutations, inducing amino acid substitu-
tions at hotspots, such as M220, G54, and G138, or nonsynonymous resistance mutations in
combination with tandem repeat (TR) in the gene promoter region, such as TR34/L98H and
TR46/Y121F/T289A [10]. TRs have been shown to increase the expression of Cyp51A [11], and
over the past years, novel TR variants have been reported, including variations in the number
of repeat duplications (e.g., triplication of TR34 and TR46 [12, 6]), as well as the length of the
repeat (e.g., TR120 [13]). As distinctly different Cyp51A alterations were found in different
(sampling) environments, the concept of a patient and an environmental route of resistance
selection was postulated [14].
Which evidence supports a patient and environmental route of
resistance selection?
Evidence for in-host resistance selection was provided through observations of patients pre-
senting with aspergillus disease due to wild-type A. fumigatus that evolved to resistant pheno-
types during triazole therapy. Microsatellite genotyping found wild-type and resistant isolates
to be isogenic, supporting the selection of resistant clones in vivo [15]. A frequent characteris-
tic of these patients is the presence of a pulmonary cavity. As A. fumigatus may undergo asex-
ual sporulation in pulmonary cavities, it is likely that genetic variation increases through the
generation of millions of spores. Resistant clones are then selected through triazole exposure.
Nonsynonymous Cyp51A mutations are typically found in this setting, and a single aspergil-
loma may contain multiple resistance mutations [16]. Genotyping indicated that the diversity
between resistant isolates with identical resistance mechanisms but recovered from different
patients was notably higher than among resistant isolates found in the environment, support-
ing de novo in-host resistance selection rather than patient-to-patient transmission.
As triazole-resistant A. fumigatus was also encountered in patients without previous triazole
exposure, the possibility of an environmental route was postulated [14,17]. Most of these
patients were diagnosed with triazole-resistant IA, and the resistance mechanisms predomi-
nantly involved TR-associated mechanisms [18,19]. Furthermore, as A. fumigatus exclusively
forms hyphae in IA, the fungus does not benefit from genetic variation induced by spore pro-
duction; thus, in-host resistance development is unlikely. Alternatively, patients may inhale
inherently triazole-resistant A. fumigatus spores, supported by the fact that in every case with a
wild-type A. fumigatus coinfection, the genotypes remain disparate [18]. Moreover, recovery
of A. fumigatus isolates from the environment harboring the same TR-associated resistance
mutations as patient isolates supported an environment route of resistance selection. Indeed,
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genotyping of clinical and environmental isolates harboring TR34/L98H or TR46/Y121F/
T289A showed phylogenetic clustering, indicating a closer genetic relatedness between them
than with wild-type control isolates. Furthermore, in a controlled experimental evolution
design, many environmental azole fungicides were found to be active against A. fumigatus to
very effectively select for resistance and, crucially, to cause cross-resistance to the medical tria-
zoles in these populations without ever being exposed to them [20]. The characteristics of both
routes of resistance selection are summarized in Table 1.
Which observations challenge the distinct association between
specific resistance mutations and the route of resistance
selection?
Although numerous studies have reported the presence of TR34/L98H, TR53, and TR46/Y121F/
T289A in clinical and environmental samples, single-resistance mutations have also been
found in settings not consistent with in-host resistance selection: the environment and from
triazole-naïve patients. A wide variety of single-resistance mutations have been cultured from
the environment, including single-resistance mutations that were also found in triazole-treated
patients (Table 2). Furthermore, recently, a CPA patient was reported who developed triazole
resistance in an A. fumigatus isolate harboring TR120 in the Cyp51A promoter [13]. The find-
ing was supported by whole-genome sequencing data, illustrating that the resistant and a pre-
viously cultured wild-type isolate were isogenic, and other potential resistance mutations in
the resistant isolate were absent. Thus, the selection of TR-associated resistance mechanisms
may not be exclusive to the environment [13]. This evidentially challenges the exclusiveness of
the association between resistance mechanism and route of resistance selection.
How can the emergence of single-resistance mutations in the
environment and TR-mutations in patients be explained?
Although the conditions present in the human host may facilitate the selection of single-resis-
tance mutations and exposure of A. fumigatus to azole fungicides the development of
Table 1. Characteristics of the patient and environmental route of resistance selection in A. fumigatus.
Patient route Environmental route
Resistance is primarily found in patients with a
pulmonary cavity
Resistance is found in all aspergillus diseases: invasive
aspergillosis, ABPA, chronic colonization, aspergilloma
Recent or ongoing triazole therapy Two-thirds of patients are triazole naïve
Isolates may have a fitness cost in culture Isolates have no apparent fitness cost
Isogenic wild-type and resistant isolates may be found
in consecutive samples from the same patient
Isogenic wild-type and resistant isolates are not found in
consecutive samples from the same patient
�Resistance mutations include single mutations in the
Cyp51A gene and non-Cyp51A (unknown) mutations
�Resistance mechanisms include single mutations in the
Cyp51A gene combined with tandem repeats in the gene
promoter
�Resistance mutations are found in clinical samples
only
�Resistance mutations are found both in clinical samples
and in the environment
Clinical samples may contain multiple different
resistance mutations
Clinical samples generally contain one single-resistance
mechanism but may also harbor wild-type isolates
Genetic typing shows high diversity in resistant
isolates from different patients
Genetic typing shows low diversity in resistant isolates
from different patients
�These statements are challenged by recent studies.
Abbreviation: ABPA, allergic bronchopulmonary aspergillosis.
https://doi.org/10.1371/journal.ppat.1007858.t001
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Table 2. Single-resistance mutations in triazole-resistant A. fumigatus recovered from azole-naïve patients and environmental samples.
Origin and
year�
Geographic
region
Sample Azole exposure Cyp51A resistance
mechanisms§ (# of
isolates)
Resistance
phenotype
Comment Reference
Clinical
2006–2009 France Clinical None G432S (1) ITC R, PCZ S,
VCZ S
[21]
2010 Germany Pulmonary
sample
None M220L (1) ITC R, PCZ R,
VCZ S
[22]
2011–2015 France Clinical No systemic
antifungal treatment
in last 6 months
A284T (1); H285Y
(1)
ITC S, PCZ R,
VCZ S
ITC R, PCZ R,
VCZ R
Also isolates reported with changes at
F46Y; M172V; N248T; D255E;
E427K; in different combinations
giving slightly elevated PCZ MICs
[23]
2013 Argentina Cornea
surface
None G54E (1) ITC R, PCZ S,
VCZ S
[24]
2014 France Pulmonary
sample
None F219I (1) ITC R, PCZ R,
VCZ S
[25]
2014� Unknown Pulmonary
sample
None Y121F (1) ITC s, PCZS,
VCZ R,
[26]
2013–2014 India Pulmonary
sample
None P216L (3)
G54R (1)
Y431C (2)
ITC R, PCZ S,
VCZ S
ITC R, PCZ S,
VCZ R ITC R,
PCZ S/R, VCZ S
[27]
Environmental
2005� Switzerland Soil n.a. Unknown (1),
F46Y, M172V,
E427K (1) §
ITC S, VCZ R
ITC R, VCZ S
In addition, several environmental
isolates with ITC MIC 2–8 mg/l were
reported without sequence
information
[28]
2007 the
Netherlands
Soil n.a. Unknown (3)
F46Y/M172V/
E427K§ (2)
ITC R, PCZ S,
VCZ R;
ITC R, PCZ S,
VCZ S;
ITC S, PCZ S,
VCZ R;
ITC S, PCZ S,
VCZ R
[29]
2009–2011 Great Britain Soil, Air n.a. Unknown (2) ITC R, PCZ R,
VCZ S-I
[30]
2011–2015 France Dust,
Patients
home
n.a. H285Y (1) ITC R, PCZ R,
VCZ R
Also, isolates reported with SNPs at
F46Y;
M172V; N248T; D255E; E427K; in
different combinations, giving
slightly elevated PCZ MICs
[23]
2011–2012 Italy Soil n.a. Unknown (1),
F46Y/M172V/
N248T/D255E (1) §
ITC R, PCZ R,
VCZ S;
ITC R, PCZ R,
VCZ I
[31]
2012–2013 Germany Soil n.a. G54A (2)
M220I (1)
ITC R, PCZ R,
VCZ S;
ITC R, PCZ R,
VCZ R
[32]
2013–2014 Tanzania,
Roemania,
India
Soil n.a. G54E (21) ITC R, PCZ R,
VCZ S
[33]
2014–2016 Taiwan Soil, Air n.a. WT cyp51A or SNPs
(5)
ITC S-R, PCZ R,
VCZ S-R
[34]
2014–2017 Italy Soil n.a. G54E ITC R, PCZ R,
VCZ S
[35]
(Continued)
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mechanisms with TRs, the distinction between a patient route and environmental route is arti-
ficial. Rather than the location where resistance is selected, characteristics of the fungus and its
environment will determine the supply of mutations and subsequent selection. Factors that are
critical include the fungal effective population size, mode of reproduction, biochemical charac-
teristics of the antifungal drug, and concentration, which ultimately determine whether resis-
tant clones will emerge. Although certain mechanisms may dominate in specific habitats, over
time we may not be able to reliably derive the route of resistance selection based only on the
resistance mechanism found due to increasing diversity of resistance mechanisms.
What is the relevance of the origin of resistance mutations?
The origin of azole resistance selection is important for management of patients with Aspergil-
lus diseases. Although the development of azole resistance can be anticipated in patients on
chronic azole therapy [39], environmental resistance can affect any patient who is prone to
develop Aspergillus disease irrespective of their azole treatment history [14,19]. In patients
with azole-resistant IA, early detection of resistance was found to be critical for survival [4]. As
most patients with IA are culture negative, molecular tests have been developed and validated
that allow detection of resistance mutations directly in clinical samples [40]. Thus far, com-
mercial PCR tests include only TR-associated resistance targets [40], and as a consequence,
other azole resistance mechanisms will not be detected. Therefore, information on the range
and frequency of resistance mutations that can be encountered in the environment is impor-
tant for development of reliable molecular tests. Furthermore, in order to halt the global spread
of environmental resistance mutations, strategies are needed that prevent or reduce the burden
of resistance induced by fungicide use.
What are our next steps?
The potentially fading boundaries between patient and environmental routes of resistance
selection is an incentive to focus on the conditions that facilitate the development, selection,
and spread of resistance genotypes, which is best approached through multidisciplinary collab-
oration and from a one-health perspective. In a recent study, targeted environmental sampling
showed high levels of azole-resistant A. fumigatus in stockpiles of flower bulb waste, green
waste, and wood chippings [41]. The common feature of these habitats was the ability of A.
fumigatus to thrive and reproduce, and the presence of azole fungicide residues [41]. Such
insights are critical to identify practices that confer a high risk for resistance selection and to
Table 2. (Continued)
Origin and
year�
Geographic
region
Sample Azole exposure Cyp51A resistance
mechanisms§ (# of
isolates)
Resistance
phenotype
Comment Reference
2015 Switzerland Soil n.a. G54R ITC R, PCZ S,
VCZ S
[36]
2015–2016 France Soil Propiconazole and
tebuconazole
Unknown (1),
P216L (1)
ITC R, PCZ R,
VCZ R;
ITC R, PCZ R,
VCZ S
[37]
2017� Colombia Soil n.a. Unknown ITC R, VCZ S [38]
�Year of publication, as date of sampling was not provided.
§Amino acid alterations that are reported in azole-susceptible and -resistant isolates.
Abbreviations: I, intermediate; ITC, itraconazole; PCZ, posaconazole; R, resistant; S, susceptible; VCZ, voriconazole.
https://doi.org/10.1371/journal.ppat.1007858.t002
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design interventions that reduce the burden of environmental resistance. Furthermore, the
common features that characterize the “hotspot” for resistance selection could be helpful to
identify additional hotspots. On a global scale, understanding the dynamics and spread of
resistance is essential to determine whether azole resistance mutations have arisen through a
single event and subsequent spread or continue to emerge in different geographic regions.
Little is known about the origin of single-resistance mutations that are recovered from the
environment. It could be that specific environmental conditions exist that facilitate the emer-
gence of these resistance mutations. Alternatively, humans harboring resistant A. fumigatus
might contaminate their environment. Indeed, a recent study indicated possible aerosol
patient-to-environment transmission of A. fumigatus in chronically colonized patients [42].
An evolutionary trajectory of the fungus that involves a phase in the human lung could change
the way we manage patients with chronic lung colonization.
Clearly, azoles play a major role in the world’s food production, and at least until alterna-
tives to chemical use are fully developed, our goal should be to retain the potential of using this
class for agricultural applications. But this should not go at the expense of the availability of
azoles for patient treatment. Thus, a better understanding of resistance selection dynamics and
spread and risk factors associated with resistance selection will help us to design measures that
prevent or control the problem in the environment as well as in patients and will improve our
ability to diagnose and manage resistance in human infection.
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